Olga Sinilnikova

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
    Ana Teresa Maia
    Cambridge Research Institute CRUK, Li Ka Shing Centre, Cancer Research UK, Robinson Way, Cambridge, CB2 0RE, UK
    Breast Cancer Res 14:R63. 2012
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  3. pmc The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    O M Sinilnikova
    Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Leon Berard, Lyon 69373, France
    Br J Cancer 101:1456-60. 2009
  4. pmc Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
    Logan C Walker
    Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 12:R102. 2010
  5. pmc The INSIG2 rs7566605 polymorphism is not associated with body mass index and breast cancer risk
    Daniele Campa
    German Cancer Research Center DKFZ, Heidelberg, Germany
    BMC Cancer 10:563. 2010

Collaborators

  • S Giraud
  • H Nevanlinna
  • R K Schmutzler
  • I Coupier
  • A C Antoniou
  • F Lalloo
  • G Rennert
  • J Simard
  • G Pichert
  • I Bieche
  • A Meindl
  • I L Andrulis
  • Lesley McGuffog
  • Ros Eeles
  • Fergus J Couch
  • Douglas F Easton
  • Debra Frost
  • Susan Peock
  • Louise Izatt
  • Sue Healey
  • Georgia Chenevix-Trench
  • Dominique Stoppa-Lyonnet
  • Andrew K Godwin
  • Susan M Domchek
  • D Gareth Evans
  • Diana Eccles
  • Sylvie Mazoyer
  • Ana Teresa Maia
  • Julian Adlard
  • Rosa B Barkardottir
  • Maria Adelaide Caligo
  • Capucine Delnatte
  • Jonathan Beesley
  • Anna Marie Mulligan
  • Xiaoqing Chen
  • Katherine L Nathanson
  • Jackie Cook
  • Noralane M Lindor
  • Jean Pierre Fricker
  • Tuomas Heikkinen
  • Daphne Gschwantler-Kaulich
  • Marcel R Nelen
  • Tim Rebbeck
  • Amanda B Spurdle
  • Martijn Verheus
  • Rosemarie Davidson
  • Christoph Engel
  • Christian F Singer
  • Per Karlsson
  • Daniele Muller
  • Brita Arver
  • Xianshu Wang
  • Helmut Deissler
  • Barbara Wappenschmidt
  • Vernon S Pankratz
  • Logan C Walker
  • Daniele Campa
  • Bruce A J Ponder
  • Suet Feung Chin
  • Laurence Faivre
  • Laurence Venat-Bouvet
  • Christiana Kartsonaki
  • Marion Gauthier-Villars
  • Mark Dunning
  • Christina N Curtis
  • Martin O'Reilly
  • Carlos Caldas
  • Shamith Samarajiwa
  • Hilmi Ozcelik
  • Gordon Glendon
  • Jeffrey N Weitzel
  • Amanda E Toland
  • Javier Benitez
  • John L Hopper
  • Siranoush Manoukian
  • Virginie Caux-Moncoutier
  • Evgeny Imyanitov
  • Saundra M Buys
  • Javier Godino
  • Maroulio Pertesi
  • Antonella Savarese
  • J Louise Jones
  • Frances P O'Malley
  • Trinidad Caldes
  • Anne Marie Gerdes
  • Emma D'Andrea
  • von Anna Wachenfeldt
  • Nicolas Sevenet
  • C Marleen Kets
  • Juul Wijnen

Detail Information

Publications5

  1. pmc Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
    Ana Teresa Maia
    Cambridge Research Institute CRUK, Li Ka Shing Centre, Cancer Research UK, Robinson Way, Cambridge, CB2 0RE, UK
    Breast Cancer Res 14:R63. 2012
    ..We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the known variable penetrance of BRCA2 mutations might be associated with this mechanism...
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  3. pmc The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    O M Sinilnikova
    Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Leon Berard, Lyon 69373, France
    Br J Cancer 101:1456-60. 2009
    ..A single nucleotide polymorphism (SNP) in the promoter region of MDM2 (309T>G, rs2279744) and a coding SNP of TP53 (Arg72Pro, rs1042522) have been shown to be of functional significance...
  4. pmc Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
    Logan C Walker
    Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 12:R102. 2010
    ..In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel approach that analysed gene expression differences to prioritise candidate modifier genes for association studies...
  5. pmc The INSIG2 rs7566605 polymorphism is not associated with body mass index and breast cancer risk
    Daniele Campa
    German Cancer Research Center DKFZ, Heidelberg, Germany
    BMC Cancer 10:563. 2010
    ..BMI is considered to be one of the measures of choice to evaluate body fatness and there is evidence that body fatness is related with an increased risk of breast cancer (BC)...